These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 660533)

  • 1. The design of pharmacological experiments using unbiased models of agonist-antagonist interaction.
    Vere DW
    J Pharmacol Exp Ther; 1978 Jun; 205(3):617-23. PubMed ID: 660533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Developments of computer-based estimation of pA2 values and associated analysis.
    Stone M; Angus JA
    J Pharmacol Exp Ther; 1978 Dec; 207(3):705-18. PubMed ID: 731426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antagonist inhibition curves and the measurement of dissociation constants.
    Barlow RB; Bond SM; Bream E; Macfarlane L; McQueen DS
    Br J Pharmacol; 1997 Jan; 120(1):13-8. PubMed ID: 9117087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rational design of receptor partial agonists and possible mechanisms of receptor partial activation: a theory.
    Zhu BT
    J Theor Biol; 1996 Aug; 181(3):273-91. PubMed ID: 8869127
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic combinations of anticonvulsant agents: what is the evidence from animal experiments?
    Jonker DM; Voskuyl RA; Danhof M
    Epilepsia; 2007 Mar; 48(3):412-34. PubMed ID: 17346245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modification of dose-response curves by effector blockade and uncompetitive antagonism.
    Pennefather P; Quastel DM
    Mol Pharmacol; 1982 Sep; 22(2):369-80. PubMed ID: 6292695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The methodology for researching the combined action of pharmacological substances by using the mathematical theory of experiments].
    Vladimirov VG; Smirnova SM; Boĭko VN
    Eksp Klin Farmakol; 1993; 56(6):59-62. PubMed ID: 8111303
    [No Abstract]   [Full Text] [Related]  

  • 9. Quantitative pharmacology or pharmacokinetic pharmacodynamic integration should be a vital component in integrative pharmacology.
    Gabrielsson J; Green AR
    J Pharmacol Exp Ther; 2009 Dec; 331(3):767-74. PubMed ID: 19779129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Principles of pharmacodynamics and their applications in veterinary pharmacology.
    Lees P; Cunningham FM; Elliott J
    J Vet Pharmacol Ther; 2004 Dec; 27(6):397-414. PubMed ID: 15601436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Statistical analysis of drug interactions.
    Mitchell CL
    NIDA Res Monogr; 1986; 68():41-64. PubMed ID: 3095655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determining the potency and molecular mechanism of action of insurmountable antagonists.
    Kenakin T; Jenkinson S; Watson C
    J Pharmacol Exp Ther; 2006 Nov; 319(2):710-23. PubMed ID: 16857731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. On the use of a dynamic approach to the estimation of dissociation constants for reversible competitive antagonists.
    Amidon GL; Buckner CK
    J Pharmacol Exp Ther; 1981 Feb; 216(2):352-6. PubMed ID: 6257889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A modified procedure for estimating pA2--equi-concentration effect method].
    Xu DZ
    Zhongguo Yao Li Xue Bao; 1989 Nov; 10(6):568-71. PubMed ID: 2641859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early integration of pharmacokinetic and dynamic reasoning is essential for optimal development of lead compounds: strategic considerations.
    Gabrielsson J; Dolgos H; Gillberg PG; Bredberg U; Benthem B; Duker G
    Drug Discov Today; 2009 Apr; 14(7-8):358-72. PubMed ID: 19162219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alternative strategies in drug development: clinical pharmacological aspects.
    Kuhlmann J
    Int J Clin Pharmacol Ther; 1999 Dec; 37(12):575-83. PubMed ID: 10599949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Models of agonist-antagonist interaction [proceedings].
    Vere DW
    Br J Pharmacol; 1976 Jul; 57(3):470P. PubMed ID: 974360
    [No Abstract]   [Full Text] [Related]  

  • 18. Experimental design and interaction analysis of combination studies of drugs with log-linear dose responses.
    Fang HB; Ross DD; Sausville E; Tan M
    Stat Med; 2008 Jul; 27(16):3071-83. PubMed ID: 18186545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tissue response as a functional discriminator of receptor heterogeneity: effects of mixed receptor populations on Schild regressions.
    Kenakin TP
    Mol Pharmacol; 1992 Apr; 41(4):699-707. PubMed ID: 1569922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of drug interactions in combined drug therapy by reflection method.
    Zheng QS; Sun RY
    Acta Pharmacol Sin; 2000 Feb; 21(2):183-7. PubMed ID: 11263269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.